FDA Grants AP Status for Dr. Reddy's PHYTONADIONE ANDA215820
The FDA has granted Abbreviated Approval (AP) status for Dr. Reddy's ANDA215820 for PHYTONADIONE.
Published: July 19, 2026
Updated: July 19, 2026
Author: Humanexa Intelligence
Therapeutic area: Hematology / Vitamin K
Asset: PHYTONADIONE
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
PHYTONADIONE
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's grant of Abbreviated Approval status to Dr. Reddy's for PHYTONADIONE introduces a new competitor in the vitamin K market. This could lead to pricing pressures and shifts in market share, necessitating strategic adjustments from existing players.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the launch timeline and market response to Dr. Reddy's PHYTONADIONE product.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.